437 results on '"Newbold, Kate"'
Search Results
2. Normal organ dosimetry for thyroid cancer patients treated with radioiodine as part of the multi-centre multi-national Horizon 2020 MEDIRAD project
3. Measurement and Incorporation of Laryngeal Motion Using cine-MRI on an MR-Linear Accelerator to Generate Radiation Therapy Plans for Early-stage Squamous Cell Cancers of the Glottis
4. Medullary Thyroid Cancer: Diagnosis and Non-surgical Management
5. Anaplastic Thyroid Cancer
6. Genomic landscape of anaplastic thyroid cancer and implications on therapy
7. Thyroid cancer
8. Screening failure in clinical trials for patients with head and neck squamous cell carcinoma: A retrospective analysis.
9. Taste dysfunction following radiotherapy to the head and neck: A systematic review
10. Molecular genotyping in medullary thyroid cancer
11. Initial results of the INSPIRE clinical trial--investigating radiation dosimetry for differentiated thyroid cancer patients.
12. Impact of antibiotic use during curative treatment of locally advanced head and neck cancers with chemotherapy and radiotherapy
13. Measurement and Incorporation of Laryngeal Motion using cine-MRI on an MR-Linear Accelerator to Generate Radiotherapy Plans for Early-Stage Squamous Cell Cancers of the Glottis
14. Targeted Molecular Therapy
15. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial
16. Thyroid
17. Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer (COSTAR; CRUK/08/004)
18. Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer
19. Incorporating spatial dose metrics in machine learning-based normal tissue complication probability (NTCP) models of severe acute dysphagia resulting from head and neck radiotherapy
20. Head and Neck Cancers
21. Introduction
22. Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy
23. A randomised controlled trial of Caphosol mouthwash in management of radiation-induced mucositis in head and neck cancer
24. Molecular Alterations and Comprehensive Clinical Management of Oncocytic Thyroid Carcinoma: A Review and Multidisciplinary 2023 Update.
25. Changes in multimodality functional imaging parameters early during chemoradiation predict treatment response in patients with locally advanced head and neck cancer
26. Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practice
27. Initial results of the INSPIRE clinical trial—investigating radiation dosimetry for differentiated thyroid cancer patients
28. Normal tissue complication probability (NTCP) modelling using spatial dose metrics and machine learning methods for severe acute oral mucositis resulting from head and neck radiotherapy
29. Assessment of fully-automated atlas-based segmentation of novel oral mucosal surface organ-at-risk
30. Comprehensive Quantitative Evaluation of Variability in Magnetic Resonance-Guided Delineation of Oropharyngeal Gross Tumor Volumes and High-Risk Clinical Target Volumes: An R-IDEAL Stage 0 Prospective Study
31. Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial
32. The Role of Pretherapy Quantitative Imaging and Dosimetry in Radioiodine Therapy for Advanced Thyroid Cancer
33. Data from Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei
34. Supplementary data from Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei
35. Supplementary Figure Captions from Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI
36. Data from A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer
37. Supplementary Figure 1 from Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI
38. Supplementary Data from Two-Stage Phase I Dose-Escalation Study of Intratumoral Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers
39. Supplementary Figure 2 from Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI
40. Supplementary Figures S1-S4 from Phase I/II Study of Oncolytic HSVGM-CSF in Combination with Radiotherapy and Cisplatin in Untreated Stage III/IV Squamous Cell Cancer of the Head and Neck
41. Supplementary Figure 6 from Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI
42. Supplementary Figure 5 from Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI
43. Figure S2A from Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study
44. Supplementary Figure 2 from Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies
45. Supplementary Figure 1 from Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies
46. Supplementary Figure Legends 1-3 from Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies
47. Supplementary Figure 3 from Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies
48. Supplementary Data from Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study
49. Supplementary Figure 3 from Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI
50. Supplementary Figure 1 from A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.